• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey

    Simply Wall St·07/10/2026 09:38:56
    Listen to the news

    Biohaven (BHVN) has just hit two key clinical milestones that are drawing fresh attention to the stock, completing enrollment in its pivotal RISE3 opakalim epilepsy trial and starting Phase 3 testing of BHV-1300 in Graves' disease.

    See our latest analysis for Biohaven.

    These clinical updates appear to sit alongside a strong recent run in Biohaven's share price, with a 30-day share price return of 51.4% and a 90-day share price return of 83.1%. However, the 3-year total shareholder return is down 31.47%, which suggests momentum has picked up lately despite a weaker longer history.

    If you are interested in other potential high-growth stories in healthcare, this could be a good moment to review a curated list of 40 healthcare AI stocks.

    After a sharp move like Biohaven's, the choice often comes down to paying up for momentum or waiting for a cooler entry. To frame that trade off, it helps to look closely at what the current valuation implies next.

    Preferred Price-to-Book of 19.5x: Is It Justified?

    On the latest numbers, Biohaven trades on a P/B of 19.5x, which puts a rich valuation on the stock at a last close of $16.79 compared with typical biotech peers.

    P/B compares the company's market value with its net assets on the balance sheet. For an early stage biopharma like Biohaven, which is currently loss making and reports no meaningful revenue, investors often lean on this metric as a rough proxy for how much the market is willing to pay for the pipeline, intellectual property and future potential versus hard assets.

    Here, the gap versus peers is wide. Biohaven's 19.5x P/B is described as expensive compared both to the broader US biotechs industry average of 2.8x and a peer group average of 9.2x, so the stock carries a premium that assumes a lot is riding on future execution rather than current financials.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 19.5x (OVERVALUED)

    However, Biohaven's rich P/B and current losses of $647.677m leave little margin for disappointment if clinical trials, including opakalim and BHV-1300, encounter setbacks.

    Find out about the key risks to this Biohaven narrative.

    Next Steps

    If this mix of renewed optimism and clear risks around Biohaven has you thinking hard, do not wait too long to form your own view. Test it against the latest data by checking the 1 key reward and 5 important warning signs.

    Looking For More Investment Ideas Beyond Biohaven?

    If Biohaven has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover fresh ideas that fit your style before others spot them.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.